These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26289304)

  • 21. Reducing Xerostomia by Comprehensive Protection of Salivary Glands in Intensity-Modulated Radiation Therapy with Helical Tomotherapy Technique for Head-and-Neck Cancer Patients: A Prospective Observational Study.
    Teng F; Fan W; Luo Y; Ju Z; Gong H; Ge R; Tong F; Zhang X; Ma L
    Biomed Res Int; 2019; 2019():2401743. PubMed ID: 31380414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma.
    Cheng JC; Chao KS; Low D
    Int J Cancer; 2001 Apr; 96(2):126-31. PubMed ID: 11291096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anatomical and dose changes of gross tumour volume and parotid glands for head and neck cancer patients during intensity-modulated radiotherapy: effect on the probability of xerostomia incidence.
    Marzi S; Pinnarò P; D'Alessio D; Strigari L; Bruzzaniti V; Giordano C; Giovinazzo G; Marucci L
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):e54-62. PubMed ID: 22138192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of radiation-induced changes to parotid glands following conventional radiotherapy in patients with nasopharygneal carcinoma.
    Wu VW; Ying MT; Kwong DL
    Br J Radiol; 2011 Sep; 84(1005):843-9. PubMed ID: 21224300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical observation of 73 nasopharyngeal carcinoma patients treated by helical tomotherapy: the China experience.
    Ren G; Du L; Ma L; Feng LC; Zhou GX; Qu BL; Xu SP; Xie CB; Ou GM; Li F; Zhang XX; Yang J
    Technol Cancer Res Treat; 2011 Jun; 10(3):259-66. PubMed ID: 21517132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors and distribution features of level IB lymph nodes metastasis in nasopharyngeal carcinoma.
    Zeng L; Zhang Q; Ao F; Jiang CL; Xiao Y; Xie HH; Tang YQ; Gong XC; Li JG
    Auris Nasus Larynx; 2019 Jun; 46(3):457-464. PubMed ID: 30528104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of protective effects on salivary and swallowing structures and improvement of late xerostomia and dysphagia by level IIb optimisation in clinical target volume of nasopharyngeal carcinoma.
    Zhou J; Wang L; Qiu T; Gao H; Wang L; Huang S; He X; Wu L
    BMC Cancer; 2024 May; 24(1):648. PubMed ID: 38802747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients.
    Zhao DW; Teng F; Meng LL; Fan WJ; Luo YR; Jiang HY; Chen NX; Zhang XX; Yu W; Cai BN; Zhao LJ; Wang PG; Ma L
    Radiother Oncol; 2023 Jul; 184():109683. PubMed ID: 37120102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Volumetric changes of the parotid gland during IMRT based on mid-treatment imaging: implications for parotid stem cell sparing strategies in head and neck cancer.
    Gjini M; Ahmed S; Kalnicki S; Tomé WA; Garg MK; Kabarriti R; Brodin NP
    Acta Oncol; 2022 Sep; 61(9):1069-1074. PubMed ID: 35978529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A nomogram for predicting late radiation-induced xerostomia among locoregionally advanced nasopharyngeal carcinoma in intensity modulated radiation therapy era.
    Yang K; Xie W; Zhang X; Wang Y; Shou A; Wang Q; Tian J; Yang J; Li G
    Aging (Albany NY); 2021 Jul; 13(14):18645-18657. PubMed ID: 34282056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment planning constraints to avoid xerostomia in head-and-neck radiotherapy: an independent test of QUANTEC criteria using a prospectively collected dataset.
    Moiseenko V; Wu J; Hovan A; Saleh Z; Apte A; Deasy JO; Harrow S; Rabuka C; Muggli A; Thompson A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1108-14. PubMed ID: 21640505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic nomogram of xerostomia for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy.
    Pan XB; Liu Y; Li L; Qu S; Chen L; Liang SX; Chen KH; Liang ZG; Zhu XD
    Aging (Albany NY); 2020 Jan; 12(2):1857-1866. PubMed ID: 32005029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation.
    Kam MK; Chau RM; Suen J; Choi PH; Teo PM
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):145-57. PubMed ID: 12694833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's ring: dosimetric analysis and clinical outcome.
    Bi XW; Li YX; Fang H; Jin J; Wang WH; Wang SL; Liu YP; Song YW; Ren H; Dai JR
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1086-93. PubMed ID: 24120822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of salivary function change in nasopharyngeal carcinoma treated by parotid-sparing radiotherapy.
    Liu WS; Kuo HC; Lin JC; Su MC; Lee JK; Chou MJ; Chou MC; Lee H
    Cancer J; 2006; 12(6):494-500. PubMed ID: 17207319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance sialography for investigating major salivary gland duct system after intensity-modulated radiotherapy of nasopharyngeal carcinoma.
    Ou D; Zhang Y; He X; Gu Y; Hu C; Ying H; Zhu G; Wu Y; Mao J; Yue L; Shen X
    Int J Clin Oncol; 2013 Oct; 18(5):801-7. PubMed ID: 22892798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.